Editorial
Cost-effectiveness evaluation of the use of PCSK9 inhibitors
Evaluación del coste-efectividad de la utilización de los inhibidores de PCSK9
Read
2298
Timeswas read the article
394
Total PDF
1904
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 45 | 15 | 60 |
| 2025 11 | 208 | 62 | 270 |
| 2025 10 | 123 | 21 | 144 |
| 2025 9 | 149 | 27 | 176 |
| 2025 8 | 139 | 29 | 168 |
| 2025 7 | 110 | 12 | 122 |
| 2025 6 | 91 | 5 | 96 |
| 2025 5 | 117 | 12 | 129 |
| 2025 4 | 46 | 4 | 50 |
| 2025 3 | 61 | 7 | 68 |
| 2025 2 | 38 | 7 | 45 |
| 2025 1 | 28 | 6 | 34 |
| 2024 12 | 24 | 4 | 28 |
| 2024 11 | 23 | 4 | 27 |
| 2024 10 | 19 | 6 | 25 |
| 2024 9 | 32 | 19 | 51 |
| 2024 8 | 21 | 13 | 34 |
| 2024 7 | 20 | 7 | 27 |
| 2024 6 | 26 | 13 | 39 |
| 2024 5 | 21 | 5 | 26 |
| 2024 4 | 20 | 1 | 21 |
| 2024 3 | 25 | 5 | 30 |
| 2024 2 | 29 | 2 | 31 |
| 2024 1 | 16 | 3 | 19 |
| 2023 12 | 9 | 2 | 11 |
| 2023 11 | 18 | 5 | 23 |
| 2023 10 | 23 | 3 | 26 |
| 2023 9 | 8 | 2 | 10 |
| 2023 8 | 11 | 1 | 12 |
| 2023 7 | 11 | 1 | 12 |
| 2023 6 | 33 | 3 | 36 |
| 2023 5 | 37 | 0 | 37 |
| 2023 4 | 39 | 0 | 39 |
| 2023 3 | 39 | 0 | 39 |
| 2023 2 | 26 | 2 | 28 |
| 2023 1 | 18 | 3 | 21 |
| 2022 12 | 10 | 2 | 12 |
| 2022 11 | 16 | 4 | 20 |
| 2022 10 | 11 | 4 | 15 |
| 2022 9 | 14 | 6 | 20 |
| 2022 8 | 6 | 8 | 14 |
| 2022 7 | 24 | 6 | 30 |
| 2022 6 | 21 | 4 | 25 |
| 2022 5 | 27 | 6 | 33 |
| 2022 4 | 18 | 14 | 32 |
| 2022 3 | 14 | 7 | 21 |
| 2022 2 | 9 | 8 | 17 |
| 2022 1 | 14 | 3 | 17 |
| 2021 12 | 14 | 9 | 23 |
| 2021 11 | 3 | 2 | 5 |
Show all
